Federal health workers have been told to submit 6,000 character self assessments as part of a recalibrated annual performance review, STAT reported, a change officials describe as making high ratings more meaningful and that staff, after the DOGE era layoffs, regard with suspicion. The Regulatory Affairs Professionals Society summarised the same reporting in its weekly FDA roundup.
Eli Lilly’s neuroscience head has signalled interest in ibogaine investments, Endpoints News reported, a single sourced item carried here as a signal rather than a transaction: no deal, amount or partner was reported. The interest sits inside a wider federal opening on the psychedelic compound, after the FDA in early October sought public input on the design of early phase ibogaine trials, with cardiac monitoring at the centre of the safety debate.
In executive moves, Endpoints News reported that Intellia Therapeutics has hired its new chief medical officer from Scholar Rock, and that a former Genentech scientist has joined Ira Mellman’s new venture Medici. Separately, the week’s two biotech IPOs held their gains on debut: Renaissance Capital tallied City Therapeutics up 24 percent and Iambic Therapeutics up 49 percent at the October 16 close, covered in full in the updated City Therapeutics story.